271 related articles for article (PubMed ID: 30076951)
1. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
Oláh G; Dobos N; Vámosi G; Szabó Z; Sipos É; Fodor K; Harda K; Schally AV; Halmos G
Eur J Pharm Sci; 2018 Oct; 123():371-376. PubMed ID: 30076951
[TBL] [Abstract][Full Text] [Related]
2. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
3. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
Westphalen S; Kotulla G; Kaiser F; Krauss W; Werning G; Elsasser HP; Nagy A; Schulz KD; Grundker C; Schally AV; Emons G
Int J Oncol; 2000 Nov; 17(5):1063-9. PubMed ID: 11029513
[TBL] [Abstract][Full Text] [Related]
4. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
5. The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma.
Fodor K; Dobos N; Schally A; Steiber Z; Olah G; Sipos E; Szekvolgyi L; Halmos G
Oncotarget; 2020 Jan; 11(2):175-187. PubMed ID: 32010430
[TBL] [Abstract][Full Text] [Related]
6. Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.
Popovics P; Schally AV; Szalontay L; Block NL; Rick FG
Oncotarget; 2014 Jun; 5(12):4567-78. PubMed ID: 24994120
[TBL] [Abstract][Full Text] [Related]
7. Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Westphal G; Halmos G; Engel JB
Cancer Res; 2005 Jul; 65(13):5857-63. PubMed ID: 15994963
[TBL] [Abstract][Full Text] [Related]
8. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
Günthert AR; Gründker C; Bongertz T; Schlott T; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
[TBL] [Abstract][Full Text] [Related]
9. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
[TBL] [Abstract][Full Text] [Related]
10. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
Bajo AM; Schally AV; Halmos G; Nagy A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
[TBL] [Abstract][Full Text] [Related]
11. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
Emons G; Sindermann H; Engel J; Schally AV; Gründker C
Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
[TBL] [Abstract][Full Text] [Related]
12. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Nagy A; Schally AV
Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
[TBL] [Abstract][Full Text] [Related]
13. In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
Arencibia JM; Schally AV; Halmos G; Nagy A; Kiaris H
Anticancer Drugs; 2001 Jan; 12(1):71-8. PubMed ID: 11272290
[TBL] [Abstract][Full Text] [Related]
14. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G
Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032
[TBL] [Abstract][Full Text] [Related]
15. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
17. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.
Günthert AR; Gründker C; Böttcher B; Emons G
Anticancer Res; 2004; 24(3a):1727-32. PubMed ID: 15274347
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system.
Günthert AR; Gründker C; Bongertz T; Nagy A; Schally AV; Emons G
Breast Cancer Res Treat; 2004 Oct; 87(3):255-64. PubMed ID: 15528968
[TBL] [Abstract][Full Text] [Related]
19. Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer.
Engel JB; Tinneberg HR; Rick FG; Berkes E; Schally AV
Curr Drug Targets; 2016; 17(5):488-94. PubMed ID: 26951061
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
Gründker C; Völker P; Griesinger F; Ramaswamy A; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2002 Sep; 187(3):528-37. PubMed ID: 12237622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
